---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-324866"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-07-30T11:05:16+00:00"
generated_at: "2026-07-30T11:10:45.251563+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# EyePoint completes enrollment in both Phase 3 DME trials of DURAVYU; topline data Q4 2027

## Summary
- Over 480 patients enrolled across COMO and CAPRI trials in five months, ahead of schedule.
- Topline 56-week data for both DME trials anticipated in Q4 2027.
- DSMC reviewed masked safety data in May 2026 and recommended continuation of both programs.
- DURAVYU evaluated in over 190 patients across four completed trials with favorable safety profile.
- Phase 3 program developed in alignment with FDA and EMA.

## SEC filing metadata
- accession: 0001193125-26-324866
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-07-30T11:05:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/0001193125-26-324866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526324866/eypt-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-324866
- JSON: https://secwatch.observer/filing/0001193125-26-324866.json
- Plain text: https://secwatch.observer/filing/0001193125-26-324866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.